Whether you’re sizing the addressable market for a specific disease area or refining your pricing assumptions for a potential new asset, you need analytics that can give you the most precise inputs, fast. We released a new analytics software, called Clarify Portfolio, to help business development and licensing (BD&L) teams make better investment decisions. It arms you with the input needed to gauge the true [...]
This month, Clarify Health hosted a webinar with Reuters Events Pharma to discuss decoding patient journeys for commercial impact. It included an all-star panel of speakers from Clarify, Eli Lilly, and Boehringer Ingelheim, and it was moderated by Reuters. Attendees were primarily from pharmaceutical and biotechnology companies, working in the [...]
Ten experts, including our CEO, Jean Drouin, MD, contributed to the November issue of PM360, “Data Overload—The Best Ways to Manage and Interpret Data.” Experts from across the life sciences industry shared their point of view on what it will take to use the right data at the right [...]
The revenue performance of a pharmaceutical drug at launch sets the stage for its commercial future. However, approximately two-thirds of new drugs fall short of first-year sales expectations. In this HLTH GoLive series webinar, “Rearchitecting the Drug Launch Model,” Manisha Gulati, Chief Operating Officer, Clarify Health, asked an expert [...]
Imagine your company was presented with an investment opportunity. The proposition: commit several hundred million dollars over 10-12 years for the potential to make billions of dollars annually for the following decade. The catch: there is a ~95% chance that you could lose everything. What would you do? Most companies [...]